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BACKGROUND/METHODS: This study evaluated human papillomavirus (HPV) type prevalence in 370 Scottish invasive cervical cancers
(ICCs) using HPV genotyping and HPV mRNA detection.
RESULTS: HPV 16 and/or 18 was detected in 72% of cancers overall and in 82% of HPV-positive cancers. HPV 45 and
16 were the most frequently transcribed types.
CONCLUSION: A significant reduction in ICC in Scotland should be achieved through the HPV immunisation programme.
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Human papillomavirus immunisation is being introduced in many
countries across the world. In Scotland, a national school-based
immunisation programme began in September 2008 for girls aged
12–17 years using HPV bivalent vaccine. The vaccine protects
against infection with high-risk HPV 16 and 18 that are thought
to contribute to around 70% of cervical cancers (http://www.
fightcervicalcancer.org.uk, 2009). However, the data used to
inform this percentage are based on worldwide meta-analyses,
which have incorporated little UK, let alone Scottish, data (Clifford
et al, 2003; Smith et al, 2007).
We undertook a sufficiently powered, systematic interrogation
of cervical cancer cases from all regions of Scotland to determine
HPV type-specific prevalence. This study was necessary to gauge
the potential impact of the immunisation programme, which so
far has achieved high uptake (93.3% for first dose and 89.5%
for second dose) for girls in second year of secondary school
(http://www.isdscotland.org/isd/5922.html, 2009).
The study was also undertaken to define a baseline prevalence
against which to monitor changes over time in HPV types
associated with cervical cancers. Acquisition of related demo-
graphic, clinical and HPV type-specific data allowed us to assess
the relationship between HPV 16/18 status, disease stage (FIGO),
disease grade and the expression profile of HPV types within
cancers with multiple infections.
MATERIALS AND METHODS
Sample collection
A representative population-based sample of Scottish invasive
cervical cancers (ICC) was achieved by selecting cases regionally
from Edinburgh, Dundee, Aberdeen, Glasgow and Lanarkshire.
Each site was asked to generate a sequential list of ICC cases,
diagnosed from 2004 working backwards. 2004 was chosen as
the most recent year for which data in the Scottish Cancer
Registry were complete. The sample included both microinvasive
and frank cancers, but not recurrent cancers. Review of cases was
performed at each site and the relevant formalin-fixed paraffin-
embedded block from the primary invasive tumour was sent to
the Scottish HPV Reference Laboratory for sectioning and HPV
testing.
Data collection
Demographic and clinical information was sent to the Scottish
Cancer Registry where laboratory and registry data were linked,
with a view to attaching demographic variables (including the
Scottish Index of Multiple Deprivation), prognostic variables
(FIGO stage and ICD-O grade of differentiation) and a unique
linkage number (to allow dates of death, when applicable, to be
added at a later date). Where necessary, data cleansing was
performed.
HPV DNA genotyping
Typing of HPV was performed using HPV INNO-LiPA (Innogenetics
NV, Gent, Belgium) according to the manufacturer’s instructions.
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nucleotide fragment of the HPV L1 gene. Briefly, 10mm paraffin
sections cut with a clean microtome knife were digested overnight
with proteinase K. Crude lysate (10ml) was subjected to PCR and
amplicons were hybridised to genotyping arrays capable of
detecting high-risk HPV types and several low-risk types. A result
of HPV ‘X’ was generated if the sample was HPV positive but could
not be attributed to a type within the detection range of the assay.
HPV mRNA detection within multiple infection
Any cancer that tested positive for 41 type, tested positive for
low-risk type(s) only or generated a result of HPV X alone was
subjected to mRNA E6/E7 expression analysis, using HPV PreTect
RNA Proofer (NorChip AS, Klokkarstna, Norway) according to the
manufacturer’s instructions. The method involves RNA extraction
before isothermal NASBA RNA amplification of full-length E6/E7.
Type-specific detection was performed using molecular beacons
corresponding to HPV types 16, 18, 31, 33 and 45.
Data analysis
Our hypothesis was that HPV 16 and 18 distributions in cervical
cancers in Scotland was no different from collated, worldwide
estimates of around 70%. To detect a prevalence of HPV type 16/18
of 70% to within 10%, we needed a sample size of 323 using a
two-sided 95% confidence interval (CI). To assess how represen-
tative our study population was, it was compared with the cancer
registry data on 1752 cervical cancers diagnosed in Scotland
from 2000–05 (http://www.scotland.gov.uk/Topics/Statistics/SIMD/
BackgroundMethodology, 2009). Socioeconomic status and age at
diagnosis were examined using w
2-tests.
Where data were available, the relationship between HPV 16
and/or 18 vs other or no HR-HPV and FIGO stages I–IV was
assessed using a w
2-test. A similar analysis was performed to assess
the relationship between HPV 16 and/or 18 positivity and ICD-O
grade of differentiation (grades I–IV).
For mRNA expression analysis, frequency of type-specific
transcripts was assessed and descriptive analysis was performed.
RESULTS
Comparison of study population with national
registry data
Of the 375 cervical cancers collated, 370 were included after data
checking in the cancer registry. Omissions included two cases
from women with permanent residence outside Scotland at time
of diagnosis, two related to recurrent disease and one to a case
of high-grade CIN. Using a w
2-test there was no evidence of
a difference between socioeconomic status (P¼0.273) or age
(P¼0.846) between the study population and the cancer registry
data based on 1752 cases, indicating that our study population was
representative. Of the 370 cases evaluated, 309 (83.5%) were
squamous cell carcinoma, 54 (14.6%) were adenocarcinoma and
7 (1.9%) were ‘other’ types.
HPV 16 and/or 18 prevalence
Comprehensive type-specific data on all DNA-positive cases are
presented in Table 1. HPV DNA was detected in 325 out of 370
cases (88%) with HPV 16 in 207 cases, HPV 18 in 66 cases and
HPV 16 and 18 in 8 cases. Overall, HPV 16 and/or 18 was detected
in 72% (265 out of 370) of cases (67–76; 95% CI). Considering only
HPV-positive cases, HPV 16 and/or 18 were detected in 82% (265
out of 325; 77–86 95% CI).
Multiple infection and non-HPV 16/18 infection
Multiple infections were detected in 36 (10%) cases (95% CI
7–13%). Interestingly, by combining cases in Scotland’s ‘central
belt’ (Edinburgh, Glasgow and Monklands), we found evidence of a
difference in the proportion of cases with multiple infections
compared with non-central belt (Aberdeen and Dundee combined)
with 7.8% more in the central belt with a 95% CI of (2–13.5),
P¼0.008. The three most prevalent types after 16 and 18 were
45, 33 and 31. A result of HPV X was generated quite frequently
(23 appearances: 11 times in isolation, 12 as part of a multiple
infection).
Association between HPV 16/18 status and FIGO stage and
grade
Table 2 depicts HPV 16/18 status vs non-HPV status according to
FIGO stage, disease grade and age. There was no evidence from the
available data of a relationship between HPV 16 and/or18 presence
and either stage (P¼0.561) or grade (P¼0.553).
Table 1 Overall distribution of HPV types in 370 invasive Scottish
cancers
Typing result Total HPV transcripts detected
64 2  none; 2 invalid
16 190 NA
18 53 NA
31 9 NA
33 6 NA
45 9 NA
52 1 NA
53 1 None
58 1 NA
59 2 NA
11, 16, 18, 45, 51, 68/73/97 1 45
16, 18, HPVX 2 16 and 31; 16
16, 31, 54 1 16
16, 18 4 16 and 18; 18; 16 and 45 and invalid
16, 31, 18 1 16 and 45
16, 39 2 16; 16
16, 45 2 Invalid and 45
16, 56 1 16
16, 68/73/97 1 None
16, HPV X 1 16
18, 31, 51, 54 1 18
18, 45, 52, 6 1 45
18, HPV X 3 18; 18; 18
31, 54 1 31
31, 54, HPV X 1 31
31, 33, 44, 52 1 31
33, 54 3 16 and 33; 31 and 33; 33
45, 53 1 45
45, HPV X 5 45; 45; 45; 45; 45
6, 45 1 45
6, 16 1 Invalid
6, 31, 45, 68/73/97 1 Invalid
68/73/97 2 None and invalid
HPV X 11 18; 3 none; 6 invalid; 1 insufficient material
None detected 45 NA
Grand total 370 32
Abbreviations: HPV¼human papillomavirus; NA¼not applicable. A result of HPV X
was generated if the sample was HPV positive but could not be attributed to a type
within the range of the assay. A result of HPV 68/73/97 indicates positivity for HPV
68, 73 or 97. Samples that tested positive for 41 type (n¼36), for low-risk types
only (n¼7) or that generated a result of HPV X only (n¼11) were also tested using
an mRNA assay that delineates HPV 16, 18, 31 and 45. Shaded numbers represent
HPV transcripts of HPV types that were not detected in the equivalent DNA moiety
of the sample.
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Of the 36 cervical cases in which multiple infections were detected,
32 proved adequate for expression analysis. In 25 out of 32 cases
only one transcript was detected, in 6 out of 32 two transcripts
were detected and in one case no transcript was detected. It was
notable that in five cases (shaded), an RNA transcript was detected
that was not reflected in the equivalent HPV DNA component. In
the seven cases in which a low-risk type was detected (4 HPV 6,
2 HPV 68/73/97 and 1 HPV 53), no transcripts were detected in
five cases, and two cases (both HPV 6) were invalid for expression
analysis. In the eleven cases in which HPV X was detected, one
tested positive for HPV 18, no transcripts were detected in three
cases, six cases were invalid for expression analysis and one case
had insufficient material for re-testing. The two most commonly
expressed transcripts were HPV 45 (number of appearances¼12)
and HPV 16 (number of appearances¼11).
DISCUSSION
The HPV vaccine is being offered through a national programme in
several parts of the world including Scotland. However, the vaccine
is not a panacea for the eradication of HPV-associated cervical
disease and is licensed only to protect against HPV types 16 and 18.
Nevertheless, the findings of this study are very positive with 82% of
a systematic collection of HPV DNA-positive ICC from across
Scotland, being positive for HPV 16 and/or 18. A meta-analysis by
Smith et al (2007) showed that HPV16/18 prevalence in Europe,
North America and Australia was 74–77% of all cases tested. Thus,
the Scottish data tally with this percentage. The next most frequently
detected types in the Scottish ICC cases were, in order of prevalence,
HPV 45, 33 and 31. Again this is an encouraging finding as there is
increasing evidence to suggest a cross-protective effect with the
bivalent vaccine for HPV types closely related to HPV 16 (HPV 31,
52 and possibly 33) and HPV 18 (HPV 45) (Jenkins, 2008).
It is notable that in our series 13 cancers (2.9%) occurred in
women aged 18–24 years, with 11 out of 13 being infected with
HPV 16 and/or 18. This is representative of collated Scottish
Registry data from 2000 to 2005 in which 52 (2.96%) of 1752 cases
were diagnosed in women o24 years. Routine cytology screening
of women occurs in Scotland from age 20. Current discussion
centres round the effectiveness of such a policy (Sasieni et al,
2009). Although we have not explored the screening history of the
young women included in this study, early screening provides the
potential for early detection and prevention of invasive disease.
It was interesting that in four cancers HPV 6 was the only HPV
type detected. An explanation for this could be that there was a
co-infecting high-risk type that was below the level of detection of
the assay. However, in a recent review, which focussed on the
classification of weakly carcinogenic HPV types, Schiffman et al
(2009) suggested that ‘HPV 6, and other low-risk types can cause
cancer in extremely rare virus–host circumstances’.
We did not find an association between HPV 16 and/or 18 positivity
and FIGO stage or disease grade. When the analysis was restricted to
HPV 16 vs absence of HPV 16, again no association with stage of
disease was found. Although this suggests that HPV type may have no
substantive impact on prognosis, it is our intention to investigate this
more directly by assessing survival according to HPV type in the study
cohort as soon as sufficient follow-up time has accrued.
Preliminary data relating to transcript detection would indicate
preferential expression of HPV 16 and interestingly HPV 45, the
latter being expressed even when present in co-infections with
HPV 16 and/or HPV 18. However, numbers are small and this
phenomenon requires further investigation.
In conclusion, this evaluation would suggest that the bivalent
prophylactic HPV vaccine will eventually have a significant impact
on the reduction of ICC in Scotland. In addition, the accumulated
data will act as a baseline against which future changes in type-
specific prevalence in cancers can be referred as HPV immuni-
sation embeds.
ACKNOWLEDGEMENTS
We are grateful to the Chief Scientist Office, Scottish Government
Health Department for funding this study (CZB/4/538). We thank
Karen Smith and Lesley Bhatti of the Scottish Cancer Registry
for their help in processing the data, Jacqui Doran for assistance in
the fieldwork procedures, and Petter Gronn and NorChip AS
for assistance with the transcript-detection element to this study.
The study received research ethics approval from the Scottish
Multicentre Research Ethics Committee (07/MRE00/25).
REFERENCES
Clifford GM, Smith JS, Aguado T, Franceschi S (2003) Comparison of
HPV type distribution in high-grade cervical lesions and cervical cancer:
a meta-analysis. Br J Cancer 89: 101–105
http://www.fightcervicalcancer.org.uk. Accessed on August 2009
http://www.isdscotland.org/isd/5922.html. Accessed on August 2009
http://www.scotland.gov.uk/Topics/Statistics/SIMD/BackgroundMethodology.
Accessed on August 2009
Jenkins D (2008) A review of cross-protection against oncogenic HPV by an
HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of
virological and clinical endpoints and implications for mass vaccination
in cervical cancer prevention. Gynecol Oncol 110(3 Suppl 1): S18–S25
Sasieni P, Castanon A, Cuzick J (2009) effectiveness of cervical screening
with age: population based case-control study of prospectively recorded
data. BMJ 389: b2968
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM
(2007) Human papillomavirus type distribution in invasive cervical
cancer and high-grade cervical lesions: a meta-analysis update. Int J
Cancer 121: 621–632
Schiffman M, Clifford G, Buonaguro M (2009) Classification of
weakly carcinogenic human papillomavirus types: addressing
the limits of epidemiology at the borderline. Infect Agents and Cancer
4: 8
Table 2 HPV 16/18 status related to age, disease stage (FIGO) and
disease grade
HPV16/18 n (%) Not HPV16/18 n (%) Total
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2 40 (78.4) 11 (21.6) 51
3 42 (73.7) 15 (26.3) 57
4 9 (60.0) 6 (40.0) 15
Not known 60 (65.9) 31 (34.1) 91
Grade
1 8 (66.7) 4 (33.3) 12
2 71 (73.2) 26 (26.8) 97
3 75 (66.4) 38 (33.6) 113
4 1 (100.0) 0 (0.0) 1
Not known 110 (74.8) 37 (25.2) 147
Age group (years)
o35 69 (80.2) 17 (19.8) 86
35–49 96 (76.2) 30 (23.8) 126
50–64 60 (74.1) 21 (25.9) 81
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Abbreviation: HPV¼human papillomavirus.
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